While Medication and conservative approaches are primary treatments, the Surgery segment provides the definitive, high-cost solution for patients suffering from end-stage, debilitating thumb arthritis that has failed non-operative management. Surgical procedures, which typically involve joint replacement (arthroplasty) or joint fusion (arthrodesis), are complex, high-revenue interventions that are critical for restoring long-term function and alleviating severe pain.

The need for surgical intervention is driven by the relentless progression of Osteoarthritis (OA), which eventually erodes the cartilage entirely, leading to bone-on-bone friction and severe disability. The success of surgical procedures relies on specialized implants and instrumentation supplied by companies like BioPro, who focus on creating durable, biocompatible replacements for the CMC joint. This ensures the market is constantly seeking innovative surgical techniques to improve outcomes and reduce recovery times.

The high cost of surgical procedures and related hospitalization is a major contributor to the market's overall value and is a key reason why Hospitals & Clinics remain the dominant end-user segment. These facilities invest heavily in the infrastructure, operating room equipment, and specialized staff required to perform hand surgery safely and effectively, particularly in high-spending markets like the United States and Canada.

Advancements in Treatment Options, such as minimally invasive arthroscopic surgery and the development of better implant materials, are making surgery a more appealing option for patients who have exhausted conservative care. This continuous improvement in surgical technology will help push the overall market valuation toward USD 1.15 Billion by 2035. To explore the specifics of surgical treatments, consult the full report at Thumb Arthritis Surgery Market.

Tags: #Surgery #Arthroplasty #Arthrodesis #JointReplacement #MinimallyInvasive